Our Story

Arcellx was founded with the goal of adding control and adaptability to the potential of cell therapy.

Received seed money to start the development of what would become the D-Domain binding scaffold in an 800 sq. ft. tech incubator space in Gaithersburg, MD.

The initial success of the fully synthetic D-Domain, along with the prototypes of the first ARC-SparX platform, helps secure Series A funding, enabling the team to expand operations.

Arcellx receives IND approval from the FDA for anitocabtagene autoleucel and closed Series B funding to kick-start clinical trials and advance pipeline of ARC-SparX therapies.

The first patient is dosed with anitocabtagene autoleucel for the treatment of relapsed or refractory multiple myeloma.
—
DECEMBER 2020
The data from the company’s ongoing Phase 1 Study of anitocabtagene autoleucel presented at ASH.

Arcellx received IND approval from the FDA for ACLX-001, a controllable cell therapy that uses the ARC-SparX platform for the treatment of multiple myeloma.
—
JUNE 2021
Arcellx secures Series C funding to continue advancing anitocabtagene autoleucel and ACLX-001.

Arcellx closes successful initial public offering and begins trading on the Nasdaq under the ticker symbol “ACLX”.
—
MAY 2022
Arcellx doses first patient in its Phase 1 clinical trial evaluating ACLX-001, the first therapeutic in the dosable and controllable ARC-SparX platform, for the treatment of patients with relapsed or refractory multiple myeloma.

Arcellx presents continued robust long-term responses from its anitocabtagene autoleucel Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at the 2022 ASCO Annual Meeting.

Kite, a Gilead Company, and Arcellx finalize a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, anitocabtagene autoleucel (CART-ddBCMA), for the treatment of patients with relapsed or refractory multiple myeloma.

Arcellx and Kite, a Gilead Company announce the design of iMMagine-3, a phase 3, randomized controlled trial designed to compare the efficacy and safety of anitocabtagene autoleucel (anito-cel) with SOC in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody.
Leadership

Chief Executive Officer












Board of Directors
Rami joined Arcellx in 2021 and serves as our Chairman and Chief Executive Officer. Most recently, Rami served as President and CEO of Nevro, beginning in 2012. Under his leadership, Nevro grew from a small private company to a public company approaching $400m in revenue and a leader in neuromodulation. Prior to Nevro, Rami was an investor with Johnson & Johnson Development Corporation (JJDC), where he led several investments including Nevro’s Series B Financing and served on the Board of Directors of several private companies including Nevro’s. Prior to joining JJDC, Rami was a Design Engineer for Advanced Neuromodulation Systems, Inc. where he led firmware design and development on several implantable spinal cord stimulators. Rami earned recognition as an EY Entrepreneur of the Year, as one of the top CEOs in the US and as one of the top CEOs for women and diversity. He is a recipient of the Bill Campbell award by Watermark for his influence, impact, and advocacy in promoting women and women’s issues. Rami received an MBA from the Wharton School of Business at the University of Pennsylvania and holds a BS in Electrical and Computer Engineering from Rutgers University School of Engineering.
Ali is a general partner at New Enterprise Associates (NEA). Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners, and Lehman Brothers. He is a member of the Board of Directors of Adaptimmune Therapeutics Plc, Black Diamond Therapeutics, CRISPR Therapeutics AG, Monte Rosa Therapeutics, Inc., Nkarta, Inc., and Korro Bio, Inc. Ali received a BS from Duke University, an MBA from the Wharton School of Business at the University of Pennsylvania, and an MD from the University of Pennsylvania School of Medicine.
Jill is a Partner at SR One. Previously, Jill worked in corporate development at Limerick Biopharma and Dynavax Technologies where she was involved in multiple pharma partnering deals, as well as substantial private and public financings. She also specialized in health care as a consultant. Jill received her BS from Duke University and her MS in Biochemistry, Cellular, and Molecular Biology from Johns Hopkins University.
Andrew brings more than three decades of strategic leadership experience as a financial executive in the biotechnology industry. Most recently, he served as Chief Financial Officer at Nevro Corp., where he built the finance and operations group from commercial launch and drove year-over-year revenue growth. Prior to that, he was the Vice President, Finance and Chief Financial Officer at Ooma, Inc., where he currently serves as a Board Member. Before that, Andrew served in the same executive capacity at Reliant Technologies, Inc. and helped complete the acquisition of the company by Thermage, Inc. Andrew’s biotechnology industry expertise also includes senior financial leadership roles at Metrika Inc., which was acquired by Bayer; Corcept Therapeutics Incorporated; and Amira Medical, which was acquired by Roche. He holds a Business Studies degree from Trinity College, Dublin University, Dublin, Ireland and is a Fellow of the Irish Institute of Chartered Accountants.
David C. Lubner, MS has served as a director of our company since August 2020. David has served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals Inc., a biotechnology company acquired by UCB S.A. in April 2020, from January 2016 until June 2020. Before joining Ra Pharmaceuticals, he served as Chief Financial Officer of Tetraphase Pharmaceuticals from its inception in 2006 to 2016, as Chief Financial Officer of PharMetrics from 1999 until it was acquired by IMS Health in 2005 and as Vice President and Chief Financial Officer of ProScript from 1996 to 1999, where Velcade® (bortezomib), a therapy widely used for the treatment of the blood cancer multiple myeloma, was discovered. David currently serves as a member of the board of directors of Cargo Therapeutics, Inc. (Nasdaq: CRGX), Dyne Therapeutics Inc. (Nasdaq:DYN), Vor Biopharma Inc. (Nasdaq:VOR), and several other private companies. He previously served on the board of directors of Nightstar Therapeutics plc from 2017 until it was acquired by Biogen in June 2019, Therapeutics Acquisition Corporation (d/b/a as Research Alliance Corp. I.), a blank check company focused on the healthcare industry, Gemini Therapeutics, Inc. and Point Biopharma, Inc. from 2021 until it was acquired by Eli Lily & Co. in December 2023. David is a former Certified Public Accountant. He received his BS in administration from Northeastern University and an MS in taxation from Bentley University.
Kristin brings 20+ years of healthcare experience, including senior leadership roles across the payer, provider and medtech sectors. Currently, she serves as the Chief Operating Officer at Blue Cross Blue Shield Association, leading strategic, operational and technology teams to support the BCBS System. Prior to this, Kristin founded and led Hopscotch Primary Care as the CEO, standing up primary care centers to serve vulnerable patient populations across rural America. Previously, she held several positions of increasing responsibility at Aetna, beginning as Chief of Staff to the CEO and Chairman, and eventually rising to President of the Great Lakes Region. Kristin’s career also included time in venture capital investing in the healthcare and biotech sectors. She holds an MBA from Harvard Business School and a BS in Biomedical Engineering from the University of Wisconsin-Madison.
Dr. Kavita Patel is currently a primary care physician in Washington DC. She is also a nonresident Fellow at the Brookings Institution where she concentrates on a number of efforts including delivery system reforms and cost containment. Recently, she was a system level executive at Johns Hopkins Health System with oversight of clinical integration and network contracting. Dr. Patel was previously a Director of Policy for The White House under President Obama and a Deputy Staff Director to the late Senator Edward Kennedy, where she focused on pandemic preparedness and health care reform. Her prior research in healthcare quality and community approaches to mental illness have earned national recognition and she has published numerous papers and book chapters on healthcare reform and health policy. Kavita currently serves on the board of directors of, SelectQuote, Inc. Dr. Patel earned an MD from University of Texas Health Science Center, an MS in Health Services Research from the University of California Los Angeles and her BA from the University of Texas at Austin.
Olivia brings more than 20 years of experience in biotech and pharmaceutical drug development, commercialization, and healthcare management. Most recently, Olivia served as Senior Vice President, BTK Franchise at Principia Biopharma which was acquired by Sanofi in 2020. Prior to that, she was the Senior Vice President for commercial activities at Proteus Digital Health, Inc., a marketing and strategy consultant, and Chief Commercial Officer at CytRx Corporation. Olivia served in a variety of roles of increasing responsibility at Genentech in sales and marketing, managed care and leading global cross-functional teams. She currently serves on the board of directors of Contineum, Inc. Olivia holds an MBA in Finance and Marketing from the University of North Carolina, Chapel Hill, and an AB from Davidson College.